320.37
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$315.64
Offen:
$315.77
24-Stunden-Volumen:
481.52K
Relative Volume:
0.98
Marktkapitalisierung:
$14.45B
Einnahmen:
$2.99B
Nettoeinkommen (Verlust:
$1.21B
KGV:
12.78
EPS:
25.06
Netto-Cashflow:
$1.13B
1W Leistung:
+3.77%
1M Leistung:
+6.52%
6M Leistung:
-13.53%
1J Leistung:
+19.67%
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Vergleichen Sie UTHR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
UTHR
United Therapeutics Corp
|
320.37 | 13.93B | 2.99B | 1.21B | 1.13B | 25.06 |
![]()
HLN
Haleon Plc Adr
|
11.33 | 49.79B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
ZTS
Zoetis Inc
|
167.14 | 72.11B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
RDHL
Redhill Biopharma Ltd Adr
|
1.76 | 4.24M | 35.75M | 11.57M | -26.25M | -3.8069 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.80 | 45.01B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.53 | 19.43B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2022-12-06 | Eingeleitet | UBS | Buy |
2022-12-05 | Eingeleitet | Goldman | Sell |
2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
2022-09-20 | Bestätigt | BofA Securities | Underperform |
2022-09-19 | Fortgesetzt | Wedbush | Outperform |
2022-02-11 | Eingeleitet | BTIG Research | Neutral |
2021-07-14 | Hochstufung | Argus | Hold → Buy |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
2019-05-17 | Hochstufung | UBS | Sell → Neutral |
2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-02-22 | Bestätigt | Barclays | Underweight |
2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
2017-12-27 | Bestätigt | Wedbush | Outperform |
2017-04-27 | Bestätigt | Wedbush | Outperform |
2017-03-30 | Eingeleitet | UBS | Sell |
2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
Ex-United Therapeutics Exec Can't Dodge IP Suit - Law360
Those who invested in United Therapeutics (NASDAQ:UTHR) five years ago are up 151% - Yahoo
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Eisenmenger Complex Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - Barchart.com
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey
Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings - Defense World
FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewswire Inc.
Zacks Research Issues Negative Estimate for UTHR Earnings - Defense World
HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals
Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News
Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin
Interesting UTHR Put And Call Options For July 18th - Nasdaq
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance
UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360
Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com
Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus
Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance
Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance
3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance
MANNKIND CORP SEC 10-Q Report - TradingView
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria
TD Cowen maintains United Therapeutics stock Buy rating - Investing.com
3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance
United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus
Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360
United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus
Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month - Seeking Alpha
US judge dismisses United Therapeutics' counterclaims over Liquidia's 'Yutrepia' - MLex
United Therapeutics (UTHR) Gets a Hold from Wells Fargo - The Globe and Mail
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - Yahoo Finance
BofA raises United Therapeutics stock target to $321 - Investing.com Australia
United Therapeutics (UTHR): Morgan Stanley Raises Price Target | - GuruFocus
BofA raises United Therapeutics stock target to $321 By Investing.com - Investing.com Canada
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains R - GuruFocus
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains Rating | UTHR Stock News - GuruFocus
United Therapeutics (UTHR): Morgan Stanley Raises Price Target | UTHR Stock News - GuruFocus
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Call Transcript - Insider Monkey
Avepoint, Meta, United Therapeutics - TradingView
United Therapeutics: Q1 Earnings Snapshot - New Haven Register
United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
United Therapeutics Reports Strong Q1 2025 Growth - TipRanks
United Therapeutics Corp. Reports Record Revenue Growth - TipRanks
Earnings call transcript: United Therapeutics Q1 2025 beats expectations - Investing.com
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):